Novacea Focuses Asentar On Pancreatic Cancer After Prostate Cancer Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although Novacea will terminate a Phase III trial of Asentar (DN-101) in advanced prostate cancer due to a high incidence of deaths in the Asentar arm, the firm is cautiously optimistic that the oncologic will have use in advanced pancreatic cancer, CEO John P. Walker said Nov. 5